Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BridgeBio Pharma Prices Public Offering Of 8,620,690 Common Shares At $29/Share

Author: Benzinga Newsdesk | March 06, 2024 03:35am

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $250.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering to be sold by BridgeBio.
The offering is expected to close on or about March 8, 2024, subject to the satisfaction of customary closing conditions

Posted In: BBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist